ATE254479T1 - Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung - Google Patents

Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung

Info

Publication number
ATE254479T1
ATE254479T1 AT98950704T AT98950704T ATE254479T1 AT E254479 T1 ATE254479 T1 AT E254479T1 AT 98950704 T AT98950704 T AT 98950704T AT 98950704 T AT98950704 T AT 98950704T AT E254479 T1 ATE254479 T1 AT E254479T1
Authority
AT
Austria
Prior art keywords
tissue
contrast
state
binding
targeted tissue
Prior art date
Application number
AT98950704T
Other languages
English (en)
Inventor
Randall B Lauffer
Stephen O Dunham
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Application granted granted Critical
Publication of ATE254479T1 publication Critical patent/ATE254479T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT98950704T 1997-10-02 1998-09-24 Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung ATE254479T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02
PCT/US1998/020182 WO1999017809A2 (en) 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Publications (1)

Publication Number Publication Date
ATE254479T1 true ATE254479T1 (de) 2003-12-15

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950704T ATE254479T1 (de) 1997-10-02 1998-09-24 Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung

Country Status (20)

Country Link
US (2) US6861045B1 (de)
EP (1) EP1019094B1 (de)
JP (2) JP2001518523A (de)
KR (1) KR20010030854A (de)
AT (1) ATE254479T1 (de)
AU (1) AU742438C (de)
BR (1) BR9812716A (de)
CA (1) CA2303426C (de)
DE (1) DE69819925T2 (de)
DK (1) DK1019094T3 (de)
ES (1) ES2206996T3 (de)
HK (1) HK1030744A1 (de)
HU (1) HUP0101245A3 (de)
IL (1) IL134985A0 (de)
IS (1) IS2041B (de)
NO (1) NO321966B1 (de)
NZ (1) NZ503402A (de)
PT (1) PT1019094E (de)
SK (1) SK4842000A3 (de)
WO (1) WO1999017809A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
WO1999017809A2 (en) * 1997-10-02 1999-04-15 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6548044B1 (en) 1999-11-22 2003-04-15 Epix Medical, Inc. Imaging sexual response
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
EP1423136A4 (de) * 2001-08-10 2007-07-25 Epix Pharm Inc Polypeptid-konjugate mit verlängerten zirkulierenden halbwertszeiten
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
CA2477836A1 (en) 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
PL1944312T3 (pl) 2003-03-03 2012-12-31 Dyax Corp Peptydy, które specyficznie wiążą receptor HGF (CMET) i ich zastosowanie
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
EP1747026A1 (de) * 2004-05-18 2007-01-31 Siemens Aktiengesellschaft Biomolekulare kontrastmittel zur kontrolle der strahlentherapie mit protonen oder ionenstrahlen
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101317100A (zh) * 2005-11-29 2008-12-03 皇家飞利浦电子股份有限公司 使用磁共振区分结合和未结合造影剂
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
CA2660717A1 (en) 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
US9423480B2 (en) * 2008-10-27 2016-08-23 The University Of Western Ontario System and method for magnetic resonance imaging
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
MX2011009716A (es) 2009-03-19 2011-10-17 Wyeth Llc Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
WO2011095898A1 (en) 2010-02-02 2011-08-11 Koninklijke Philips Electronics N.V. Functional imaging
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
EP2983581B1 (de) * 2013-04-08 2023-11-15 Sunnybrook Research Institute Verfahren zur abbildung von biomarkern für kardiale thermoablationsläsionen
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
WO2015089505A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Coaxial ablation probe and method and system for real-time monitoring of ablation therapy
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
EP3270951B1 (de) 2015-03-16 2020-09-09 California Institute of Technology Botulinum-neurotoxin-spezifische abscheidungsmittel, zusammensetzungen und verfahren zur verwendung und herstellung
CN108290927B (zh) 2015-07-15 2022-06-24 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
EP3519425B1 (de) 2016-09-29 2024-02-28 Indi Molecular, Inc. Zusammensetzungen zum nachweis, zur hemmung und zur bildgebung von indolamin 2,3-dioxygenase 1 (ido1) und verfahren zur herstellung und verwendung davon
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US20190370956A1 (en) 2018-05-30 2019-12-05 General Electric Company Contrast imaging system and method
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
CA2539215A1 (en) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Diagnostic imaging contrast agents with extended blood retention
TW319763B (de) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19529512C2 (de) 1995-08-10 2000-11-23 Siemens Ag Verfahren zur Phasenkontrast-MR-Angiographie und Anordnung zur Durchführung des Verfahrens
DE19543785A1 (de) 1995-11-24 1997-05-28 Philips Patentverwaltung MR-Verfahren und Anordnung zur Durchführung des Verfahrens
EP0907379B1 (de) * 1996-04-01 2004-06-02 Epix Medical, Inc. Bioaktivierte diagnostische bilderzeugungskontrastmittel
IT1283650B1 (it) 1996-08-02 1998-04-23 Bracco Spa Chelati paramagnetici ad alta relassivita' in siero
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
WO1999017809A2 (en) * 1997-10-02 1999-04-15 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza

Also Published As

Publication number Publication date
EP1019094B1 (de) 2003-11-19
CA2303426A1 (en) 1999-04-15
IS5399A (is) 2000-03-10
JP2006077020A (ja) 2006-03-23
JP2001518523A (ja) 2001-10-16
KR20010030854A (ko) 2001-04-16
NO20001707D0 (no) 2000-04-03
IL134985A0 (en) 2001-05-20
PT1019094E (pt) 2004-03-31
ES2206996T3 (es) 2004-05-16
US6861045B1 (en) 2005-03-01
US7175829B2 (en) 2007-02-13
AU742438B2 (en) 2002-01-03
US20050118103A1 (en) 2005-06-02
DE69819925D1 (de) 2003-12-24
DE69819925T2 (de) 2004-09-02
WO1999017809A3 (en) 1999-05-20
CA2303426C (en) 2008-09-23
NO20001707L (no) 2000-05-31
NO321966B1 (no) 2006-07-31
HK1030744A1 (en) 2001-05-18
WO1999017809A2 (en) 1999-04-15
EP1019094A2 (de) 2000-07-19
BR9812716A (pt) 2000-08-22
NZ503402A (en) 2002-03-01
AU9668698A (en) 1999-04-27
AU742438C (en) 2003-05-22
IS2041B (is) 2005-09-15
HUP0101245A3 (en) 2003-10-28
SK4842000A3 (en) 2000-11-07
HUP0101245A2 (hu) 2001-08-28
DK1019094T3 (da) 2004-02-16

Similar Documents

Publication Publication Date Title
ATE254479T1 (de) Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung
BR9708470A (pt) Agentes de contraste bioativados para formação de imagem para diagnósticos
HUP0202635A2 (hu) Multimer leképzőszerek, eljárás ezek célbajuttatására multilocusos kötés útján és alkalmazásuk
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
BR9711009A (pt) Polipeptidio tendo um polimero solÚvel em gua n-terminal covalentemente ligado
DE69410466D1 (de) Verfahren und zusammensetzungen zur erhöhung des bild-kontrastes
DE69605954D1 (de) Anti-Streuungs-Röntgenstrahlungs-Gittervorrichtung für medizinische diagnostische Radiographie und Verfahren zur Gitterherstellung
DE69528703D1 (de) VERFAHREN, REAGENZIEN UND TESTSATZ ZUR DIAGNOSE UND GEZIELTE SIEBTESTUNG FÜR p53 MÜTATIONEN
ES2117670T3 (es) Derivado de hidroxamato e hidrazida de poliaminas y su uso medico como agentes quelantes.
EA199800881A1 (ru) Способ т1 - взвешенной магниторезонансной визуализации органов ретикуло-эндотелиальной системы
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE244024T1 (de) Sterilisationsschutzmittel und verfahren zur sterilisation
ATE452906T1 (de) Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
DE69732370D1 (de) Spinresonanz kontrastmittel für das blut
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
FR2766728B1 (fr) Dispositif anti-vibration pour instrument de jeu de balle
DE69831348D1 (de) Blutcholesterinsenkung durch die in vivo fällung von gallenbestandteilen mit gruppe ii oder -iii -metallverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1019094

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee